中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1257 records (took 0.028 seconds)

    QUANTITATIVE MICROARRAY OF INTACT GLYCOLIPID CD1D INTERACTION AND CORRELATION WITH CELL-BASED CYTOKINE PRODUCTION
    703.
    发明申请
    QUANTITATIVE MICROARRAY OF INTACT GLYCOLIPID CD1D INTERACTION AND CORRELATION WITH CELL-BASED CYTOKINE PRODUCTION 有权
    定量微晶玻璃纤维素CD1D相互作用和与细胞因子生产的相关性

    公开(公告)号：US20090275483A1

    公开(公告)日：2009-11-05

    申请号：US12423728

    申请日：2009-04-14

    Applicant: Chi-Huey Wong ,  Pi-Hui Liang

    Inventor： Chi-Huey Wong ,  Pi-Hui Liang

    IPC: C40B30/04 ,  C40B40/12

    CPC classification number: C40B30/04 ,  C40B40/12 ,  G01N2333/70539 ,  G01N2405/10

    Abstract: The protein CD1d binds self and foreign glycolipids for presentation to CD1-restricted T cells by means of TCR recognition, and activates TH1 and TH2 chemokines release. Accordingly, a variety of glycolipid ligands were attached to a microarray surface and their binding with CD1d investigated. An α-galactosyl ceramide (α-GalCer) bearing a carbamate group at the 6′-OH position was tethered to the surface and the dissociation constant with CD1d determined. Competition assays were used to determine the dissociation constants (Ki) of the new and intact glycolipids. The para-fluoroheptaphenyl-modified α-GalCer was found to bind most strongly with CD1d (Ki 0.14 μM), two orders of magnitude stronger than α-GalCer and more than three times more selective for IFN-γ release. Various α-GalCer analogs were analyzed and the results showed that the binding affinity of glycolipids to CD1d correlates well with IFN-γ production, but poorly with IL-4 secretion by NKT cells, suggesting that tighter binding ligands could bias cytokine release through the TH1 pathway.

    Abstract translation: 蛋白质CD1d通过TCR识别结合自身和外来糖脂呈递给CD1限制性T细胞，并激活TH1和TH2趋化因子释放。 因此，将各种糖脂配体连接到微阵列表面，并研究它们与CD1d的结合。 在6'-OH位置带有氨基甲酸酯基团的α-半乳糖神经酰胺（α-GalCer）被束缚于表面，并且确定了CD1d的解离常数。 使用竞争测定来确定新的和完整的糖脂的解离常数（Ki）。 发现对 - 氟苯哌啶修饰的α-GalCer与CD1d（Ki0.14μM）最强结合，比α-GalCer强两个数量级，对于IFN-γ释放是选择性的三倍以上。 分析各种α-GalCer类似物，结果表明，糖脂对CD1d的结合亲和力与IFN-γ产生良好相关，但与NKT细胞的IL-4分泌差异较小，表明更紧密的结合配体可能通过TH1偏置细胞因子释放 途径。

    THREE-DIMENSIONAL MICROSCOPIC MAGNETIC RESONANCE ANGIOGRAPHY
    704.
    发明申请
    THREE-DIMENSIONAL MICROSCOPIC MAGNETIC RESONANCE ANGIOGRAPHY 有权
    三维微观磁共振成像

    公开(公告)号：US20090274352A1

    公开(公告)日：2009-11-05

    申请号：US12434077

    申请日：2009-05-01

    Applicant: Chen CHANG ,  Chien-Yuan LIN ,  Jyh-Horng CHEN

    Inventor： Chen CHANG ,  Chien-Yuan LIN ,  Jyh-Horng CHEN

    IPC: G06K9/00 ,  G06T15/00

    CPC classification number: G01R33/5635 ,  G01R33/5601 ,  G01R33/5602 ,  G01R33/5608

    Abstract: A method comprises performing a first T2-weighted imaging (T2WI) on a subject; injecting the subject with a contrast agent after performing the first T2WI; and waiting a predetermined period of time before performing a second T2WI on the subject. The first T2WI and second T2WI are then co-registered. The co-registered first T2WI and co-registered second T2WI are then trimmed. A ΔR2 map is then determined based on each pixel of the trimmed first T2WI and corresponding pixels of the trimmed second T2WI. A three-dimensional map is constructed based on the ΔR2 map.

    Abstract translation: 一种方法包括对受试者执行第一T2加权成像（T2WI）; 在执行第一T2WI后用造影剂注射受试者; 并且在对该对象执行第二T2WI之前等待预定的时间段。 然后第一个T2WI和第二个T2WI被共同注册。 然后修改共同注册的第一个T2WI和共同注册的第二个T2WI。 然后基于修剪的第一T2WI的每个像素和修剪的第二T2WI的相应像素来确定DeltaR2映射。 基于DeltaR2映射构建三维地图。

    REISHI F3 SUB FRACTION POLYSACCHARIDES AND METHODS OF USING SAME
    705.
    发明申请
    REISHI F3 SUB FRACTION POLYSACCHARIDES AND METHODS OF USING SAME 有权
    REISHI F3 SUB分级多糖和使用它们的方法

    公开(公告)号：US20090263897A1

    公开(公告)日：2009-10-22

    申请号：US12244709

    申请日：2008-10-02

    Applicant: Shu-Mei Liang ,  Yen-Po Chen ,  Wen-Bin Yang ,  Chi-Huey Wong

    Inventor： Shu-Mei Liang ,  Yen-Po Chen ,  Wen-Bin Yang ,  Chi-Huey Wong

    IPC: C12N5/02 ,  C07K14/37 ,  C07H1/00 ,  C12N5/00

    CPC classification number: A61K39/0002 ,  A61K2039/55588

    Abstract: The present disclosure relates to the discovery of methods of isolating subfractions of an F3 Reishi extract, and of administration of these novel isolates to eukaryotic cells in order to induce certain immumodulatory, hematopoeitic and tumor-inhibiting phenotypic changes in those eukaryotic cells, mediated through particular toll-like receptor (TLR) and other transmembrane receptors. F3 subfractions F301 and F331 have demonstrated that F331 is capable of activating at least TLR-2 while F301 is capable of activating at least TLR-2, TLR-4, and TLR-5.

    Abstract translation: 本公开涉及发现分离F3赖氏提取物的亚组分的方法，以及将这些新型分离物施用于真核细胞，以便诱导那些通过特异性介导的那些真核细胞中的某些免疫调节，造血细胞和肿瘤抑制表型变化 toll样受体（TLR）和其他跨膜受体。 F3亚分数F301和F331已经证明F331能够至少激活至少TLR-2，而F301能够至少激活TLR-2，TLR-4和TLR-5。

    Asymmetric subspace watermarking
    707.
    发明授权
    Asymmetric subspace watermarking 有权
    不对称子空间水印

    公开(公告)号：US07587063B2

    公开(公告)日：2009-09-08

    申请号：US11355013

    申请日：2006-02-16

    Applicant: Wen-Liang Hwang ,  Jeng-Nan Tzeng ,  I-Liang Chern

    Inventor： Wen-Liang Hwang ,  Jeng-Nan Tzeng ,  I-Liang Chern

    IPC: G06K9/00

    CPC classification number: G06T1/005 ,  G06T2201/0052 ,  H04K1/00

    Abstract: According to an asymmetric watermarking technology, which is particularly resistant to projection attack, an original image is analyzed to obtain its watermarking space. The watermarking space is then divided to obtain two orthogonal subspaces g and h. An embedding key G, which is a matrix and which columns form bases of subspace g, is selected and a matrix H, HTG=0 is calculated. Columns of matrix H form bases of subspace h. A detecting key D, which equals the sum D= GT=BHT, wherein B is a matrix, is calculated, and a watermark w is obtained and embedded into the original image φ0 to obtain a watermarked image φw=φ0+Gw, wherein Dφ0=m0 is not a 0 vector.

    Abstract translation: 根据对投影攻击特别有抵抗力的非对称水印技术，分析原始图像以获得其水印空间。 然后将水印空间划分成两个正交子空间g和h。 选择作为矩阵并且形成子空间g的基础的嵌入密钥G，并且计算矩阵H，HTG = 0。 矩阵H的列形成子空间h的基础。 计算等于总和D = GT = BHT的检测键D，其中B是矩阵，并且获得水印w并将其嵌入原始图像phi中以获得水印图像phiw = phi0 + Gw，其中Dphi0 = m0不是0向量。

    Type of soluble pentacene precursor
    708.
    发明授权
    Type of soluble pentacene precursor 失效
    可可并五苯前体的类型

    公开(公告)号：US07572939B2

    公开(公告)日：2009-08-11

    申请号：US11351399

    申请日：2006-02-10

    Applicant: Tahsin J. Chow ,  Kew-Yu Chen ,  Jiunn-Jye Hwang

    Inventor： Tahsin J. Chow ,  Kew-Yu Chen ,  Jiunn-Jye Hwang

    IPC: C07C49/00 ,  C07C15/00 ,  B05D3/02

    CPC classification number: C07C49/665 ,  C07C4/16 ,  C07C35/44 ,  C07C43/188 ,  C07C2603/90 ,  C07C15/20

    Abstract: A novel soluble pentacene (C22H14) precursor 6,13-dihydro-6,13-methanopentacene-15-one, a method for its production and intermediates therefor as well as pentacene films and coated surfaces. Thermolysis of the precursor at 150° C. to 350° C. induces an expulsion of carbon monoxide to generate pentacene in high yield. The high solubility of the precursor compound, as well as its production of non-contaminated pentacene, makes it an excellent material in the application of organic thin film transistors on surfaces.

    Abstract translation: 一种新颖的可溶并五苯（C22H14）前体6,13-​​二氢-6,13-​​甲基多烯-15-，其制备方法及其中间体以及并五苯膜和涂布表面。 在150℃至350℃下热分解前体引起一氧化碳的排出，以高产率生成并五苯。 前体化合物的高溶解度以及其未污染并五苯的生产使其成为在表面上应用有机薄膜晶体管的优异材料。

Patent Agency Ranking